Blue Cross Blue Shield of Louisiana Lowers Patient Eligibility Requirements for TMS Treatment
Blue Cross Blue Shield of Louisiana has recently made an important change in patient eligibility requirements for Transcranial Magnetic Stimulation ...
Tag: BWAY
Analyst Ratings and Price Targets for BrainsWay NASDAQBWAY
Analyst Ratings for BrainsWay (NASDAQ:BWAY) as of November 18, 2023: Bullish: 4 Somewhat Bullish: 1 Indifferent: 0 Somewhat Bearish: 0 ...
Impressive Financial Results and Promising Future Outlook for BrainsWay Ltd
BrainsWay Ltd. has just released its financial results for the third quarter of 2023, and the numbers are impressive. The ...
Impressive Third Quarter Earnings Report and Positive Outlook for BrainsWay
On November 15, 2023, BrainsWay (NASDAQ:BWAY) released its third quarter earnings report, revealing an EPS of $-0.01. This exceeded analysts' ...
Expansion of Deep TMS Treatment for US Military Service Members
On September 20, 2023, BrainsWay, a renowned global leader in advanced noninvasive neurostimulation therapies for mental health disorders, made an ...
BrainsWay Expands Reach and Impact in Northeast US through Strategic Partnership with Treatment Provider
On September 5, 2023, BrainsWay, a renowned global leader in advanced noninvasive neurostimulation treatments for mental health disorders, made an ...
BrainsWay Expands Deep TMS Platform for Mental Health Disorders
On June 21, 2023, BrainsWay, a leading global provider of advanced noninvasive neurostimulation treatments for mental health disorders, announced the ...
Analyst Reiterates Positive Rating on BrainsWay Despite Decreased Price Target
On May 18, 2023, Steven Lichtman, an analyst at Oppenheimer, has reiterated his positive rating on BrainsWay (NASDAQ:BWAY) and maintained ...